Prednisolone + theophylline + cyclosporine
Prednisolone + theophylline + cyclosporine has been studied in 1 paper since 2020: 1 observational study in people. The newest paper, Nov 25, 2020: “Bronchiolitis obliterans syndrome is associated with increased senescent lymphocytes in the small airways”.
1 paper studies it1 findingUpdated
See all 1 papers on prednisolone + theophylline + cyclosporine
At a glance
The findings reach cells, none yet in people. 1 lab in 1 country.
- 1 lab in 1 country
- Funder: University of Adelaide
- Humans1
What did studies of prednisolone + theophylline + cyclosporine find?
1Studies of prednisolone + theophylline + cyclosporine measured one outcome, IFN-gamma and TNF-alpha production.
IFN-gamma and TNF-alpha production
downin human cells1
1 study
IFN-gamma and TNF-alpha production
downin human cells1
Prednisolone + theophylline + cyclosporine inhibits IFN-gamma and TNF-alpha production in human cells (combined treatment of SA CD28null CD8+ T and NKT-like cells in culture).
“Treatment with prednisolone + theophylline + cyclosporin A inhibited IFN-γ and TNF-α production by SA CD28null CD8+ T and NKT-like cells additively.”
Cellscombined treatment of SA CD28null CD8+ T and NKT-like cells in culturesmall airways1 μmol/liter prednisolone, 5 mg/liter theophylline, 2.5 ng/ml cyclosporine A
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation